Rating: Neutral | Target price range: RMB 8.1–8.6 (Base case: FY2026E BPS RMB 9.58 × 0.85–0.90x PB) Current price: RMB 8.04 (close on 2026-10-28) | Total market cap: approx. RMB 45.67 billion (total share capital 5.681 billion shares, A+H) | Time horizon: 6–12 months Margin of safety: approx. +0.7% (base fair-value floor RMB 8.1 vs current price) | Probability-weighted expected value: approx. RMB 8.5 (approx. +5% vs current price) Subject: Guolian Minsheng Securities Co., Ltd. (A-share 601456.SH / H-share 01456.HK), a mid-sized full-license broker; completed the share-issuance absorption merger of Minsheng Securities in January 2025, with total share capital increasing from 2.83 billion shares to 5.681 billion shares
Guolian Minsheng delivered solid results in its first full year after consolidating Minsheng Securities: revenue of RMB 6.739 billion (+11.6%) in the first three quarters of 2026, net profit attributable to shareholders of RMB 2.108 billion (+19.6%), and adjusted (ex-non-recurring) profit of RMB 2.099 billion (+21.8%). However, quarterly growth decelerated sequentially (Q1 +32.1% → Q3 +9.0%), and the core issue is ROE — annualized at roughly 5.3%, still well below mid-cap peers such as Founder (8.0%) and Zheshang (approx. 8.7%), and also below its own cost of equity. The current price of RMB 8.04 corresponds to 0.84x PB (BPS RMB 9.52, as of 2026-09-30), the lowest level since listing and an approx. 14% discount to the median PB of four comparable peers; yet solving the PB-ROE framework backwards (r≈9.25%, g≈0), 0.84x already embeds a sustainable-ROE recovery expectation of approx. 7.8%, whereas the company's weighted ROE from 2022–2025 was only 2.19%–4.63% — the valuation is at a "historical bottom," not "significantly mispriced." The controlling shareholder's share-increase commitment has been triggered (no less than approx. RMB 81.34 million within 6 months), a RMB 100–200 million cancellation-type buyback is underway, and governance gaps have been filled — bottom signals are highly certain — but the total support capital represents only approx. 0.6% of market cap. Goodwill of RMB 14.072 billion (26% of net assets attributable to shareholders), the parent company's capital leverage ratio only approx. 1.1 percentage points above the regulatory warning line, and receding market turnover (weekly average approx. RMB 1.58 trillion in late October) are three key downside variables. Conclusion: Neutral — the current price sits at the lower edge of the base fair-value range (RMB 8.1–8.6); the margin of safety is insufficient to support an active allocation. Confirmation signals on the right side: turnover holding above RMB 2 trillion, completion of share increase and appointment of new President, and FY2026 net profit attributable to shareholders ≥ RMB 2.3 billion.
Key evidence:
Net profit attributable to shareholders for the first three quarters was RMB 2.108 billion (+19.6%), adjusted +21.8%; Q2 standalone at RMB 919 million (+22.3%) was the year's high point, with Q3 falling back to RMB 693 million (+9.0%, -24.6% QoQ). 2025Q4 standalone was only RMB 246 million (seasonal concentration of year-end compensation accruals and impairments), so a mechanical YoY rebound in Q4 off a low base is highly likely; the "apparent resilience" of full-year growth warrants a discount. The stock's position at its 52-week low (RMB 8.04 is the 52-week low, -29.5% from the peak) mainly reflects a sector-wide pullback — the company's YTD performance ranks mid-range within the SW securities sector, sector PB has fallen to roughly the 12th percentile of the past five years, and market turnover has receded from the May 2026 peak (monthly daily average RMB 3.2 trillion) to RMB 1.83 trillion in September and approx. RMB 1.58 trillion weekly in late October; the individual-stock discount from the successive departures of President/Vice Presidents during integration is a secondary factor. Note: the Q3 report was disclosed after market close on 2026-10-28, so the RMB 8.04 price did not yet reflect this data.
Key evidence:
The current PB is the lowest since listing (note: the 2025 consolidation caused an approx. 3x jump in share capital/net assets, breaking the historical percentile series' comparability — it serves only as a reference for "degree of premium flush-out"), an approx. 14% discount to the 0.98x median of Founder 1.00x / Zheshang 1.06x / Zhongtai 0.95x / Industrial 0.84x. But solving PB=(ROE−g)/(r−g) backwards, 0.84x implies a sustainable ROE of approx. 7.8% (approx. 6.9% on peer cross-section methodology), corresponding to net profit attributable to shareholders of approx. RMB 4.2 billion — versus the reality of annualized approx. RMB 2.81 billion and a weighted ROE range of only 2.19%–4.63% from 2022–2025. Zero-growth EPV is approx. RMB 4.65/share (below BPS because ROE 5.3% < cost of equity 9.25% — the mathematical root of trading below book); the gap of approx. RMB 3.4 (42%) between current price and EPV is the option premium the market pays for "ROE recovery." That sell-sides assign 1.2–1.3x PB targets while forecasting only 4.4%–4.5% ROE for 2026E shows the marginal pricer is not explicitly requiring a 7%–8% ROE threshold — the gap between these two frameworks is precisely where the expectation disagreement on this stock lies.
Key evidence:
Each of the three prerequisites of the recovery path has cracks: ① Turnover — weekly daily average turnover of approx. RMB 1.58 trillion in late October, margin balance receding from the June peak of RMB 3.03 trillion to approx. RMB 2.43 trillion in late October (approx. -20%), with an adverse trend direction; ② Investment banking — Minsheng Securities' investment banking is the core value increment of the merger, but 2026H1 investment banking revenue fell 15% YoY and the Soochow-measured IPO pipeline under review was zero (diverging from Guotai Haitong's "26H1 IPO underwriting scale +101% YoY" and the Q3 report's contract liabilities +51% signal; the actual state of pipeline rebuild awaits exchange acceptance data for verification); ③ Costs — the 2026H1 expense ratio fell to approx. 63.4% (from 67.5% prior year); integration dilution is materializing but modestly. Founder (FY2025 weighted 8.0%) and Zheshang (2026H1 annualized approx. 8.7%) prove mid-cap brokers can reach 8%, but that stems from years of accumulated retail/asset-management capabilities or regional endowments; this report's 2027E ROE base assumption is only 4.9%–5.6%, and if either turnover or investment banking falls through, ROE stalling near 5% would push PB-ROE support down to 0.65–0.75x (approx. RMB 6.2–7.2).
Key evidence:
The consideration for acquiring 99.26% of Minsheng Securities was approx. RMB 29.5 billion (2.64 billion shares × RMB 11.17), implying approx. 1.9x PB, while Minsheng Securities' FY2025 net profit was only RMB 988 million — a static return of approx. 3.3% implied by the consideration. The annual report explicitly discloses that the Minsheng cash-generating unit's recoverable amount was determined via market-approach P/B, so a sharp decline in the brokerage sector PB would directly depress the recoverable amount (year-end 2025 conclusion: no impairment). Stress test: a 20% impairment against Minsheng goodwill (RMB 12.929 billion) would reduce BPS by approx. RMB 0.46 (-4.8%); a 20% impairment on total goodwill would be approx. -RMB 0.50 (-5.2%). Meanwhile, the parent company's capital leverage ratio fell from 16.09% at end-2024 to 10.71% at end-2026Q3 (warning line 9.6%), and LCR fell from 185% to 149%; on- and off-balance-sheet assets expanded at approx. RMB 12.5 billion per quarter in the first three quarters of 2026, implying only approx. 1–2 quarters of buffer at that pace — thereafter the company must either passively shrink prop trading/margin financing (earnings downgrade) or raise capital at a discount (a private placement is infeasible with A-shares below book; H-shares trade at only 0.29x PB, and a placement would dilute BPS by approx. 5%–8%).
Key evidence:
The increase commitment was triggered by "share price closing below 80% of the issue price of RMB 11.17 (RMB 8.936) for 20 consecutive days" — a binding obligation, not a discretionary statement; the RMB 100–200 million buyback plan (cap RMB 13, expiring 2026-11-10) had executed RMB 100.15 million by end-September, reaching the floor, and is designated for cancellation. But total support capital (increase floor RMB 81 million + buyback ceiling RMB 200 million) is approx. RMB 280 million, only approx. 0.6% of market cap — against a market cap of approx. RMB 45.7 billion and daily turnover of approx. RMB 130 million, it is a signal-based rather than absorption-based support. On the supply side, a common misconception needs correcting: most of the unlock impact from merger consideration shares has already materialized — restricted A-shares are down to only 855 million shares (15.05%), of which the 812 million shares maturing in January 2028 belong to the controlling shareholder, which is fulfilling its increase commitment under a "whichever is later" lock-up arrangement; the remaining approx. 1.83 billion shares gradually became tradable during 2026 (merger counterparties such as Fengquanyu and Tibet Tengyun are already listed as unrestricted holders, with partial pledges), and a small unlock of 42.96 million shares by Jiaxing Hourun Zehui occurs on 2027-03-01. The A-shares trade at an approx. 192% premium to H-shares (H-shares at HKD 3.245 ≈ RMB 2.76, only 0.29x PB) — the same asset priced nearly 3x apart in two markets; any A-share recovery may be absorbed by the "expensive leg," and a rising share-price center can ultimately only come from earnings validation, not valuation sentiment.
| Metric (RMB 100 million unless noted) | FY2023 (Guolian standalone) | FY2024 (Guolian standalone) | FY2025 (consolidated Minsheng) | 2026Q1-3 (consolidated, latest period) |
|---|---|---|---|---|
| Operating revenue | 29.55 | 26.83 | 76.73 | 67.39 |
| Net profit attributable to shareholders | 6.71 | 3.97 | 20.09 | 21.08 |
| Adjusted net profit (ex-non-recurring) | 5.94 | 3.81 | 19.50 | 20.99 |
| Weighted ROE (%) | 3.89 | 2.19 | 4.16 | 3.95 (first three quarters, annualized approx. 5.3%) |
| Net assets attributable to shareholders (period-end) | 177.69 | 185.84 | 524.90 | 541.04 (2026-09-30) |
| Total assets (period-end) | 871.29 | 972.08 | 2,032.18 | 2,505.81 |
| Net assets per share (RMB) | 6.28 | 6.57 | 9.24 | 9.52 |
| Net cash flow from operating activities | -7.14 | 140.57 | -54.45 | 211.09 |
| Goodwill (period-end) | — | — | 140.72 | 140.72 |
| Parent company net capital (period-end) | — | — | 184.43 | 238.94 |
| Risk coverage ratio (%, parent) | — | 275.08 | 304.82 | 341.74 |
| Capital leverage ratio (%, parent) | — | 16.09 | 14.30 | 10.71 |
| Annual cash dividend | — | 1.59 (RMB 0.56 per 10 shares) | 3.41 (RMB 0.60 per 10 shares) | — |
Note: As a financial institution, broker-specific metrics such as gross margin / free cash flow / net debt-EBITDA are structurally not applicable, and are therefore not listed; earnings quality is instead assessed via net capital and risk-control metrics (see E1). FY2023/FY2024 are pre-merger Guolian Securities standalone figures, not retrospectively restated; FY2025 onwards consolidate Minsheng Securities, so YoY comparisons across 2024/2025 are not directly comparable. Operating cash flow is dominated by swings in client funds (FY2025 reflects RMB +6.77 billion in funds lent to clients and RMB +5.85 billion occupied by trading financial assets) and does not reflect earnings quality.
Reasons for metric changes (items with YoY ≥ ±20%, with company explanations): FY2025 revenue +185.99%, net profit attributable +405.49%, total assets +109.05%, net assets attributable +182.44% — all due to the consolidation of Minsheng Securities in January 2025; the company noted item by item in the statement-change items "mainly due to the addition of a consolidated subsidiary," reflecting a methodology switch rather than organic growth. Goodwill rose from RMB 1.15 billion to 14.072 billion (+1131.59%), of which RMB 12.929 billion arose from the business combination of Minsheng Securities under non-common control. Net fee and commission income +122.03%; besides consolidation, the company disclosed linkage with "market daily average stock-fund turnover +70.19%." FY2024 net profit attributable -40.80% reflects the pre-merger Guolian standalone methodology (weak 2024 market conditions); the summary did not attribute it separately. For the first three quarters of 2026: net interest income +88.12%, explained by the company as "mainly due to growth in daily average funds lent and increased margin financing interest income"; fair-value change gains -236.79% to -RMB 225 million, "mainly due to fair-value changes in trading financial assets"; cash and equivalents +77.91%, "mainly due to increased proprietary deposits at period-end"; bonds payable +32.77%, "mainly due to increased corporate bond issuance"; FY2025 non-operating expenses +1028.97% to RMB 34.07 million, "mainly due to increased tax late-payment penalties and provisions for expected litigation losses."
Q3 standalone revenue was RMB 2.169 billion (+7.02%, -20.1% QoQ), net profit attributable RMB 693 million (+8.98%, -24.6% QoQ), adjusted +15% YoY. By business line (first three quarters cumulative): net brokerage fee income of RMB 2.118 billion (+35.3%, 31.4% of revenue) remained the primary driver, matching the strong market with H1 daily average stock-fund turnover of RMB 3.24 trillion (+106.5%); prop trading (investment income + fair-value changes) at RMB 2.940 billion (-1.0%, 43.6% of revenue), comprising investment income of RMB 3.165 billion (+12.9%) and fair-value changes of -RMB 225 million — negative for the third consecutive reporting period; the pattern of supporting profits via disposal gains persists. Investment banking at RMB 683 million (-0.7%) is still digesting consolidation benefits, with no inflection point visible; asset management RMB 611 million (+16.0%); net interest income RMB 195 million (+88.1%, margin financing expansion). Against sell-side consensus: FY2026E net profit attributable approx. RMB 2.61 billion (EPS RMB 0.46, n=3), with the first three quarters completing 80.8%; the street implies approx. RMB 500 million for Q4 standalone — versus only RMB 246 million in 2025Q4 (year-end compensation and impairment concentration). This report believes a Q4 in the RMB 240–440 million range better fits seasonality, i.e., our FY2026E (RMB 2.35–2.55 billion) is 6%–10% below consensus. The Q3 report was disclosed after market close on 2026-10-28, so the market's pricing reaction is not yet observable.
Business model: A balance-sheet-driven, full-license mid-sized securities firm (brokerage & wealth management / investment banking / asset management / credit / prop trading & market making). After consolidating Minsheng Securities in 2025, total assets reached RMB 250.6 billion with leverage (total assets / net assets attributable to parent, including client funds) of 4.63x. Revenue structure is roughly "half fee-based, half investment": FY2025 fee income (brokerage + IB + AM) was RMB 3.784 billion, 49.3% of revenue; prop trading was RMB 3.458 billion, 45.1%. Revenue is highly correlated with market turnover and pricing power is weak (commission rates and fund fee rates are declining industry-wide; the company itself cites "mitigating pressure from declining commission rates").
Cash content and recurring nature of earnings: A broker's operating cash flow is dominated by swings in client funds (OCF / net profit attributable to parent for FY2023–2026Q1-3: -1.06 / +35.4 / -2.71 / +10.0; direction oscillates but the basis is internally consistent, with the company attributing each period to changes in client funds / margin financing / trading assets), so this metric is not discriminating for this business model. More effective tests: ① non-recurring / attributable net profit = 97% (FY2025), minimal one-off impact; ② earnings carry high "market content" — prop trading is 43%–45% of revenue, fair-value changes negative for three consecutive periods (FY2024 -RMB 978M / FY2025 -RMB 311M / 2026Q1-3 -RMB 225M), investment income relies on realized disposals, and unrealized gains inventory is steadily depleted; ③ OCI for 2026H1 was -RMB 1.089 billion (unrealized losses on RMB 12.893 billion of investments in other equity instruments bypass the P&L), with net asset growth diverging from profit.
Capital returns: Weighted ROE was 2.19%–4.63% over 2022–2025 and roughly 5.3% annualized in 2026, persistently below cost of equity (~9%) — book profits generate insufficient capital returns; book growth relies mainly on balance-sheet expansion rather than return rates, which is the root cause of the below-book valuation. Compare mid-sized peers Founder at 8.0% and Zheshang at 6.7% (FY2025): the capital-efficiency gap is clear.
Capital adequacy and risk metrics (replacing industrial CapEx dimension): As of 2026-09-30, parent net capital was RMB 23.894 billion (+29.6% vs end-2025), risk coverage ratio 341.74%, LCR 149.32%, NSFR 144.64% — all above regulatory thresholds. However, the capital leverage ratio of 10.71% (warning line 9.6%) has trended down from 16.09% at end-2024, leaving shrinking runway for balance-sheet expansion (see C4 for details).
Red flags: IB subsidiary Guolian Minsheng Underwriting & Sponsorship posted FY2025 net loss of RMB 106M and 2026H1 loss of RMB 38M (elevated headcount costs in the first post-consolidation year); goodwill / attributable net assets = 26.0%; payout ratio plunged from 39.9% (FY2024) to 17.0% (FY2025) — per-share returns systematically diluted after share count doubled.
Consistency of words and deeds: pragmatic, mostly delivering. ① Integration commitments — the annual report pledges "orderly advancement of integration with Minsheng Securities"; actual progress: renamed 2025-02, all IB projects under review migrated to Guolian Minsheng Underwriting & Sponsorship 2025-09, Minsheng's 1.92 million brokerage clients switched trading systems in one go with "zero failures" 2025-10, final 0.02% stake acquired via judicial auction in 2026-07 for 100% ownership; independent directors assessed integration as "progressing well, results as expected" — delivered. ② Rating agency view — in 2025-02 CCXI upgraded the issuer rating from AA+ to AAA citing "rapidly rising industry standing and asset scale post-merger"; FY2025 total assets +109%, 2025 IPO underwriting ranked 7th industry-wide — delivered. ③ Shareholder return plan (2024–2026 "regular cash dividends") — dividend amounts continued but payout ratio fell from 39.9% to 17.0% — partially delivered. No habit of quantified earnings guidance; no high-profile missed forecasts found.
Shareholder friendliness: neutral to weak. Positives: RMB 100–200M cancellation-type buyback launched 2026-08 (RMB 100M executed); controlling shareholder's increase commitment being honored. Negatives: the 2021 private placement of 454M shares and the 2025 share issuance plus supporting fundraising doubled total share count to 5.681 billion shares, heavily diluting existing holders' stakes and per-share metrics; FY2025 payout ratio of 17% is well below top brokers' 30%+; dividend yield only 0.75%.
Risk signals: dense executive turnover as integration closes out — 2026-08-21 President Ge Xiaobo resigned (original term to 2028-12, "for personal reasons," board confirmed no disagreement), 08-08 non-executive director resigned, 09-18 Vice President Hu Youwen resigned (remaining as head of the research institute, which is slated to be folded into the wealth management subsidiary), 10-28 Wang Jinling / Jiang Jie joined the board while the new president remains unfilled; in 2025 the company and subsidiaries received at least 8 regulatory measures (including 3 corrective orders: derivatives trading violations, bond business internal-control deficiencies, failure to report material matters, and integrity-compliance system deficiencies); FY2025 tax surcharges + litigation provisions of RMB 34.07M are the financial footprint of compliance costs.
| Segment | % of Revenue | Segment Margin | YoY (consolidated basis, not comparable) | One-line business logic |
|---|---|---|---|---|
| Brokerage & Wealth Management | 35.9% | 35.28% (+4.57pp) | +180.3% (2026H1 +55.5%) | Commissions + product sales + fund advisory (AUM RMB 14.51bn); high market beta |
| Securities Investment (prop/market making) | 27.2% | 76.83% (+37.68pp) | +858.3% (2026H1 -29.6%) | Barbell strategy + FICC market making + equity derivatives; main volatility source |
| Investment Banking | 12.0% | -9.96% (-10.78pp) | +171.3% (2026H1 -25.0%) | Minsheng IB merger drives scale jump, but high staffing costs and subsidiary losses |
| Asset Management & Investments | 9.7% | 6.00% (-13.48pp) | +5.0% (2026H1 +58.0%) | Brokerage AM RMB 196bn + Guolian Fund RMB 212.6bn + PE |
| Credit Trading | 8.8% | 96.65% (-1.26pp) | +165.5% (2026H1 +31.3%) | Margin financing RMB 28.1bn (market share 0.93%) + stock pledge RMB 1.08bn |
| Others (international/futures etc.) | 7.3% | -118.77% | +159.0% | Includes futures, Hong Kong subsidiary and HQ items |
The profit engine is securities investment (prop trading), not the largest-revenue brokerage segment: a rough "revenue share × segment margin" estimate of each segment's contribution to consolidated P&L gives prop ~20.9%, brokerage ~12.7%, credit ~8.5%, and IB -1.2% (loss drag) — of the revenue scale gained via consolidation, only prop trading is truly high-margin, and it is precisely the most volatile and market-dependent piece. Gross margin spread is nearly 87pp (prop 76.8% vs IB -10.0%): prop revenue is financial asset spread and market-making income, naturally high-margin; IB is a "people" business, where the Minsheng team's compensation costs are front-loaded while project revenue converts with a lag — the -15% IB revenue decline in 2026H1 reflects this mismatch. Latest structure for 9M2026: brokerage 31.4%, prop 43.6%, IB 10.1%, AM 9.1% — prop share rising further, increasing earnings' market sensitivity.
Accounting red flags (with source evidence):
Cross-period consistency: ① weighted ROE 3.89%→2.19%→4.16%→3.95% (5.3% annualized); consolidation boosted profit but share count doubled, so ROE only mildly recovered — consistent with the IR framing of "per-capita revenue/profit growing YoY on a consolidated basis." ② Parent regulatory metrics: LCR 185.05%→177.13%→137.09%→149.32%, capital leverage ratio 16.09%→14.30%→11.03%→10.71% — buffers narrowing trend-wise; the company states each period that "liquidity risk is manageable," consistent with the metrics' direction but without flagging the narrowing slope. Overall, no signs of aggressive revenue recognition or profit dressing; the main issues are "earnings' dependence on market conditions" and "transparency of goodwill test assumptions."
1. Market data and multiples: Current price RMB 8.04 (close of 2026-10-28, the 52-week low; 52-week range RMB 8.04–11.40, -29.5% from peak); market cap ~RMB 45.67bn. PB(LF) 0.84x (BPS RMB 9.52, 2026-09-30) — lowest since listing (the 2025 consolidation broke the time series, so historical percentile serves only as a "risk premium cleared" reference, not a headline cheapness signal); PE(TTM) ~19.4x (TTM attributable profit RMB 2.354bn; distorted by the consolidation switch, reference only). Dividend yield 0.75%. A/H: H shares at HKD 3.245 (same-day close) × 0.84968 ≈ RMB 2.76; A-share premium over H ~192%, H-share PB only 0.29x. Peer benchmark (PB as of 2026-10-28 close, ROE FY2025 weighted):
| Company | PB (x) | FY2025 Weighted ROE (%) | Key differences |
|---|---|---|---|
| Guolian Minsheng | 0.84 | 4.16 | Consolidation integration + 26% goodwill + governance volatility discount |
| Industrial Securities | 0.84 | 4.81 | Dual public-fund platforms as profit stabilizer; same PB with 0.65pp higher ROE |
| Zhongtai Securities | 0.95 | 3.12 | Driven by prop trading elasticity |
| Founder Securities | 1.00 | 8.02 | Ping An control + retail wealth; highest ROE |
| Zheshang Securities | 1.06 | 6.70 | Guodu acquisition (small scale), regional endowment |
Cross-sectional conclusion: PB-ROE fit is neutral-to-low — same 0.84x as Industrial but with ROE 0.65pp lower; 0.84x is not a "significantly cheap" mispricing within the sector.
2. Market-implied expectations: Backing out via PB = (ROE − g)/(r − g), r = 9.25%, g = 0, the 0.84x implies a sustainable ROE of ~7.8%, corresponding to attributable profit of ~RMB 4.2bn; the current price requires profit to rise from the current annualized RMB 2.81bn to RMB 4.2bn (+50%), whereas reality is only ~5.3% annualized ROE in the first post-consolidation year, never exceeding 4.63% over 2022–2025. Sell-side consensus (FY2026E EPS RMB 0.46 / RMB 2.61bn profit; median target price RMB 12.0; 12 Buy + 3 Overweight, no Hold/Sell) is 40%+ more optimistic than this report; its implied Q4 single-quarter RMB 500M and ROE recovery slope both lack interim verification. But the reverse also holds — if turnover recovers and integration delivers, 7%–8% ROE has precedent among mid-sized brokers, in which case this report's base case would be systematically too low. This is the stock's largest expectation gap.
3. Three-layer value (EPV): Asset value = book BPS RMB 9.52 (stressed: ~RMB 7.05/share ex-goodwill); EPV (zero growth) ≈ RMB 4.65/share (normalized attributable profit RMB 2.435bn → EPS RMB 0.43 ÷ r 9.25%; equity basis, net profit ≈ FCFE) — this report computes EPV at ~58% of the current price and the growth option at ~42%. Interpretation: over half the current price is supported by asset value, but nearly 40% pays for a "ROE recovery option" whose exercise depends on turnover and integration (see C3) — one cannot say "the market prices only zero growth"; quite the opposite, the market has prepaid nearly half the recovery expectation. The mathematical root of the below-book valuation is ROE (5.3%) < r (9.25%): as long as this gap fails to narrow, trading below book is a rational steady state, not a mispricing.
4. Three scenarios and odds (pricing basis: FY2026E BPS RMB 9.58 × target PB):
| Scenario | Probability | Fair Range | vs Current | Deciding Factors |
|---|---|---|---|---|
| Bear | 25% | RMB 6.3–7.1 | -17% (midpoint 6.7) | Turnover receding to RMB 1.5tn + prop drawdown + 20% goodwill impairment (BPS → RMB 9.05), PB 0.70–0.78x (anchor: comparable sample's recent lows of 0.79–0.80x + discount for ROE < 4%) |
| Base | 50% | RMB 8.1–8.6 | +4% (midpoint 8.35) | Turnover center RMB 2–2.5tn + gradual synergies (2027E ROE ~5.5%), PB 0.85–0.90x (anchor: peer median 0.98x adjusted 8–13% for ROE gap and goodwill discount; historical center 1.82x unusable as target due to series break; Huachuang's 1.15x used only as bull-case upper anchor) |
| Bull | 25% | RMB 10.0–11.0 | +31% (midpoint 10.5) | Turnover back to RMB 3tn (demonstrated by RMB 3.47tn in Jan 2026) + ROE converging toward 7%, PB 1.05–1.15x (anchor: Zheshang 1.06x @ ROE 8.7%, Huachuang target 1.15x, 52-week high RMB 11.40 ≈ 1.20x — three mutually corroborating sources) |
External coordinates: lowest sell-side target RMB 11.54 (Guotai Haitong after its 2026-09-03 downgrade, 1.2x 2026E PB), highest RMB 14.01 (Huachuang 2025-10-31, 1.3x) — no target price in coverage is below the current price; sell-side bears are absent. This report's bear case is an independently constructed stress assumption (turnover + impairment + sector-trough PB), not comparable to sell-side "lowest target price" methodology, and its boundary is not raised just because the sell-side floor implies +44%. Probability-weighted expected value ~RMB 8.5 (~+5% vs current): downside to bear midpoint -17%, upside to bull midpoint +31%; distribution mildly positive-skewed but with limited confidence — the odds structure is "watchable, not cheap enough."
5. Own earnings forecast (earnings reconciliation anchor): FY2026E revenue RMB 8.1–8.5bn, attributable profit RMB 2.35–2.55bn (midpoint RMB 2.435bn, EPS RMB 0.43, implying Q4 single-quarter RMB 240–440M); FY2027E revenue RMB 8.8–9.7bn, attributable profit RMB 2.6–3.0bn (ROE 4.9%–5.6%). Versus consensus (2.61 / 2.78bn), FY2026 is 6%–10% lower (the gap is entirely Q4 seasonality) and FY2027 is broadly in line. Management gives no quantitative guidance; qualitative actions are buyback + share increase + integration progress.
Conclusion: reasonably cheap — target price RMB 8.1–8.6, safety margin ~+0.7%. Separate quality (ROE 5.3%, 26% goodwill, governance volatility) from price (0th-percentile PB, low end of peers): the price is indeed at the bottom, but under a PB-ROE framework it is cheap for a reason; the 42% option premium left for "recovery" is already not thin. The "undervalued" label needs support from ROE rising above 6% or a reversal in the turnover trend — currently neither is present.
1. Industry Size: Per the Securities Association of China (150 securities firms, unaudited): in 2025 the industry posted total revenue of RMB 541.171 billion, net profit of RMB 219.439 billion, total assets of RMB 14.83 trillion, and net assets of RMB 3.34 trillion; in 2026H1, revenue was RMB 329.810 billion (+31.4%) and net profit RMB 138.664 billion (+23.5%) — half-year profit already exceeded full-year 2023 (RMB 137.8 billion), with total assets rising to RMB 17.23 trillion. In 2025, the 43 listed securities firms posted net profit attributable to parent of RMB 212.8 billion (+43.8%). Volume foundation of growth: A-share average daily turnover rose from ~RMB 1.0 trillion in 2024 to RMB 1.73 trillion in 2025 (full-year turnover of RMB 420.21 trillion, an all-time high) to ~RMB 2.7 trillion in Jan–Sep 2026; however, marginal momentum has clearly decelerated — average daily turnover peaked at RMB 3.2 trillion in May 2026, then shrank month by month to RMB 1.83 trillion in September and ~RMB 1.58 trillion weekly average in late October; margin financing balance fell from the June 25 peak of RMB 3.03 trillion to ~RMB 2.43 trillion in late October (-20%), with margin trading accounting for 7.9% of turnover (second-lowest of the year). IPO normalization without a surge: 100 deals/RMB 67.4 billion in 2024 → 116 deals/RMB 131.8 billion in 2025 → 81 deals/RMB 95.8 billion through late July 2026. Sell-side research broadly expects 2026 full-year results to rise modestly on 2025's high base (J.P. Morgan forecasts industry earnings +17% in 2026H2); this report's volume data suggest that view faces a stress test in Q4.
2. Value Chain and Value Distribution: Upstream is the capital base and funding side (shareholder capital, bond issuance/short-term commercial paper/structured income notes) and exchange/CSD infrastructure — funding cost is the core variable for capital-intensive businesses; top brokers with three consecutive years of AA ratings (risk adjustment factor 0.4) enjoy significantly lower funding costs than small and mid-sized peers, while Guolian Minsheng benefits relatively on funding from the AAA rating of its Wuxi SOE parent; the midstream is the licensed securities firms themselves, with the industry revenue mix in 2026H1: brokerage RMB 104.1 billion (35.7%, back to the largest revenue line), prop trading RMB 113.1 billion (34.3%), net interest RMB 40.5 billion (12.3%), investment banking ~RMB 18.5 billion (5.6%), asset management RMB 12.1 billion (3.7%), and investment advisory RMB 5.1 billion (+57.2%, fastest growth); downstream are retail investors (4.92 million new accounts opened in January 2026), institutional clients, and issuers. On value distribution, brokerage and investment banking fees face continuous downward pressure from downstream (commission transparency, IPO concentration among top firms), while excess profits concentrate in prop trading and market-making under "license + capital" constraints — Guolian Minsheng's FY2025 revenue mix (brokerage + investment banking at 39.1%) has a higher share of asset-light fee businesses, with weaker pricing power over downstream.
3. Supply-Demand and Competitive Landscape: Supply side = licenses (essentially no new issuance; acquisition premia remain high — Guolian Group paid RMB 9.105 billion for 30.3% of Minsheng Securities in 2023, ~1.95x PB) + net capital; the M&A consolidation wave of 2024–2026 has shrunk the number of effective players: Guotai Junan absorbed Haitong (total assets of RMB 2.5 trillion, first in both key metrics), Guolian merged Minsheng, Guosen merged Wanhe, Western merged Guorong, Zheshang took control of Guodu — all completed — while CICC's absorption of Dongxing/Xinda has passed CSRC review and is progressing — the industry has moved from "trading M&A expectations" to "harvesting consolidation profits." Concentration keeps rising: revenue CR10 ~57.6% (+10.4pp over ten years), net profit CR10 ~64%, 2026H1 IPO underwriting CR5 at 76% (vs. 59% a year earlier); top 10 by total assets account for 60.4% (comparable sample). Competitive intensity: a persistent brokerage commission price war, "too many players chasing too few deals" in investment banking, and sharp divergence in prop trading; substitution threats come from internet platforms (East Money/Tonghuashun siphoning retail trading) and bank wealth management/public funds diverting wealth-management flows. Guolian Minsheng's position in the growth: margin financing market share ~0.92%–0.94%, 3.55 million brokerage clients, RMB 3.0 billion in 2025 IPO underwriting (industry No. 7, 2.3% market share), fund advisory AUM of RMB 14.51 billion (among the industry's leaders) — share trend pointing upward.
4. Cycles and Regulation: The industry is in a high-level cooling phase within an upcycle — turnover, margin balances, and client margin deposits (RMB 4.45 trillion at end-2026H1, +57.8%) are all at historically high levels but momentum is slowing; leading indicators to watch are whether average daily turnover can return above RMB 2 trillion, the margin financing inflection point, and the pace of IPO filings. Regulatory main lines: ① the first-tier investment bank policy (2024; cultivating 10 leading firms within 5 years and 2–3 international investment banks by 2035) plus the "Six M&A Measures" directly enabled this deal (the first broker M&A to pass CSRC review after the New Nine Measures); ② the new net capital risk indicators rules (effective January 2025) release capital differentially by classification rating — AA-rated firms enjoy a 0.4 factor, favoring highly rated institutions in leveraging up and raising ROE; ③ counter-cyclical margin regulation (on 2026-01-19, the margin financing ratio was raised from 80% to 100%), marginally suppressing interest income elasticity; ④ "supporting the strong and restricting the weak" in classification ratings — Guolian Minsheng faced multiple regulatory measures in 2025 that pressure its classification; a downgrade would tighten its capital factors, squeezing the company alongside its balance-sheet expansion needs.
5. Peer Benchmarking Table (data detailed in E6 table): Compared with four mid-sized peers, Guolian Minsheng's relative weakness is ROE (4.16% vs. Founder 8.02%/Zheshang 6.70%), and its relative strengths are investment banking elasticity (Minsheng IB ranked No. 7 in 2025 IPOs; Founder had no IPO pipeline as of end-March 2026) and the client/pipeline pool from the merger; 2026H1 revenue growth of +13.9% lagged Zheshang (+49.3%), Zhongtai (+46.8%), and Founder (+29.6%), at the low end of the peer group — the high base (first quarter of consolidation) and investment banking drag are the main causes.
6. Company Positioning in the Industry: A niche challenger. Ranked No. 19–20 by total assets industry-wide (Guolian standalone was No. 30 pre-merger) and around No. 24 by net assets attributable to parent — scale is already in the top 20, but profitability (ROE) sits in the bottom tier of listed brokers. Three layers of moat: ① the SOE background of Wuxi Guolian Group (23.86% shareholding) provides low-cost funding and regional resources (56 branches in Jiangsu + Minsheng's 26 in Henan, complementary); ② the Minsheng investment banking label — No. 7 in IPO underwriting and No. 1 in NEEQ listing sponsorship deals, with a distinctive Beijing Stock Exchange/SME investment banking franchise, though the empty 2026H1 pipeline is a consolidation-period growing pain; ③ first-mover status in broad wealth management — among the first batch of fund advisory pilots, with RMB 14.51 billion in AUM (+49%). Management targets "a comprehensive industry ranking within the top ten" (Gu Wei, strategic statement, February 2026); moving from No. 19 to No. 10 requires not just consolidation but an order-of-magnitude improvement in ROE — at the current annualized 5.3%, ranking gains will mainly come from consolidation and balance-sheet expansion rather than organic profitability.
Broker valuation and risk analysis cannot follow the industrial-company framework; three defining dimensions:
① Net capital and risk indicators are "hard budgets": Broker balance-sheet expansion (prop trading, margin financing, market-making) is rigidly constrained by net capital and risk capital reserves; as indicators approach warning lines, firms must either stop expanding (earnings downgrades) or raise capital (dilution). Guolian Minsheng parent-company basis: net capital RMB 23.894 billion, risk coverage ratio 341.74% (ample), capital leverage ratio 10.71% (1.11pp above the 9.6% warning line, down 5.4pp since end-2024), LCR 149.32% (warning line 120%), NSFR 144.64% — risk coverage and liquidity indicators remain safe, but rapid depletion of the capital leverage ratio is currently the tightest constraint; +32.8% in bonds payable over the first three quarters of 2026 (surge in corporate bond issuance) is precisely a transitional form of trading debt for capital. Note also the dual parent/subsidiary accounting: in August the company issued a net capital guarantee commitment for Minsheng Securities — intra-group capital deployment is already being used to the fullest.
② Business-line structure determines the source of earnings elasticity: Brokerage is a "volume business" (one-way declining commission rates; revenue = market share × turnover × rate), investment banking is a "people business" (pipeline-to-execution-to-revenue lags 12–24 months; post-consolidation, this project is in a "compensation upfront, revenue lagging" mismatch period), and prop trading is a "capital business" (directional + non-directional strategies; the industry's prop trading revenue share of 34.3% in 2026H1 ceded the top spot back to brokerage). Guolian Minsheng's divergence in the first three quarters of 2026 — brokerage +35.3%/prop trading -1.0%/investment banking -0.7% — reflects the different clocks of the three businesses: brokerage feeds on current turnover, prop trading on realizing gains from positions built last year, and investment banking on the 2024–2025 pipeline — meaning that even if turnover recovers, investment banking revenue repair will lag by 2–4 quarters.
③ Pricing dislocation from dual A/H listing: H shares of A+H brokers trade at persistent discounts (40%–70% is the sector norm); Guolian Minsheng's H-share discount of 65.7% (A-share premium 192%) sits at the wider end; H-share free float is only 7.79%, and historically the A-H price gap has mostly converged via A-share declines. Implication for this stock: the A-share "cheapness" at 0.84x PB needs an asterisk next to the H share at 0.29x — same asset, same net assets, and the offshore market prices it at less than 40% of the A-share price; any A-share buy thesis based on "repair from below book value" must answer "why is the H share more wrong." Additionally, Ruijun Asset increased its H-share stake to 6.2% in September (HKEX disclosure of interests) — offshore capital is already positioning on the left side; this is corroborating evidence of a bottom zone, but it also signals that under the same thesis, the H share's odds are significantly better than the A share's.
Overall rating: Neutral, confidence 0.55, time horizon 6–12 months. Guolian Minsheng's investment story is "consolidation pushed scale into the top 20, but ROE remains at the tail of listed brokers" — the historical-bottom pricing at 0.84x PB already embeds a considerable amount of repair expectations (options at 42% of spot); with turnover ebbing, an empty investment banking pipeline, and the twin constraints of goodwill and capital metrics unresolved, the current price of RMB 8.04 sits at the lower edge of the base fair-value range (RMB 8.1–8.6), with a safety margin of only ~+0.7% — neither a significant left-side entry point nor a structural short setup (the share purchase commitment + cancel-type buybacks + 52-week low + sector PB at the 12th percentile provide downside buffers). Strategy: stay on the sidelines: use RMB 8.6 (upper edge of base case) as the profit-taking reference, RMB 7.0 (upper edge of bear case) as the thesis-reassessment line; right-side confirmation signals = average daily turnover holding above RMB 2 trillion for a full month, completion of the share purchase and appointment of the new president, and FY2026 net profit attributable to parent ≥ RMB 2.3 billion with the investment banking revenue decline narrowing to single digits — if two of the three materialize, the base case should be revised up to 0.95–1.05x PB.
Key risks: Goodwill impairment testing is sensitive to sector PB declines (a 20% provision equals -RMB 0.46/share); the capital leverage ratio may hit the warning line within 1–2 quarters, with possible dilution from a discounted H-share placement (BPS -5%–8%); if turnover breaks below RMB 1.5 trillion, brokerage + prop trading would suffer a double hit, breaking the base case; if personnel turmoil persists (further delays in appointing the new president, attrition of core investment banking/research teams), the consolidation discount will become entrenched. Key catalysts: share purchase execution announcements (window until 2027-03-30), a new buyback round after the current one expires (2026-11-10), the new president appointment, the FY2026 annual report (late March 2027), cross-border business ramp-up after the RMB 2.0 billion capital injection into the Hong Kong subsidiary arrives in tranches, and sector beta repair driven by a recovery in market turnover.
Data and methodology notes: Financial data in this report come from the company's periodic reports (FY2023/FY2024 are on the former Guolian Securities standalone basis; from FY2025 onward, Minsheng Securities is consolidated and comparative periods are not retrospectively restated; year-over-year comparisons across periods are annotated in each instance); price and market cap are frozen at the 2026-10-28 close (RMB 8.04); the H-share price of HKD 3.245 is the same-day close, at an exchange rate of HKD 1 = RMB 0.84968; peer PB figures are on the 2026-10-28 close basis, and ROE figures are on the FY2025 annual report weighted basis.